Ligand Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ligand Pharma (LGND) Tops Q1 EPS by 23c; Raises Outlook
May 6, 2020 4:04 PM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.89, $0.23 better than the analyst estimate of $0.66. Revenue for the quarter came in at $33.2 million versus the consensus estimate of $26.53 million.
Our first quarter financial results feature strong sales of Captisol to partners evaluating remdesivir in multiple... More
